Clario has announced a partnership with the Mobilise-D consortium to integrate digital mobility outcomes (DMOs) with its Opal wearable sensor system, offering a comprehensive assessment of patient movement.
The partnership is aimed at enhancing the capture of patient mobility data in clinical trials.
Go deeper with GlobalData
DMOs offer significant improvements over traditional clinical scales by providing objective, reliable, accurate, and sensitive measurements of human movement.
As part of the Mobilise-D consortium, Clario contributed technology and expertise to the e-clinical outcome assessments (eCOA) during the development of these algorithms.
Clario is now applying these validated Mobilise-D algorithms in a study involving patients with multiple sclerosis (MS) to establish the technical equivalence of its Opal precision motion device.
The integration of mobility performance data from wearable sensors with eCOA is expected to enhance clinical outcomes and complement Clario’s existing offerings in medical imaging, cardiac, and respiratory endpoints, catering to a wide range of clinical trial requirements.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataClario precision motion product management and scientific affairs vice-president Kristen Sowalsky said: “It has been a privilege to contribute to the Mobilise-D consortium and advance digital mobility data for use in clinical trials.
“These developments are integral for demonstrating real-world patient outcomes, particularly in neuroscience where mobility insights outside of clinical settings are essential to assess treatment efficacy and quality-of-life.”
According to Clario, the use of DMOs in clinical trials represents a significant advancement in the field.
The company’s experience in eCOA data capture during the technical and clinical validation studies has prepared it to offer advanced solutions that incorporate Mobilise-D algorithms with its wearable sensors.
This initiative is set to improve the assessment of mobility performance and deliver more accurate and reliable DMOs, which are crucial in evaluating treatments, especially in conditions such as MS.
